CON Concentra Group Holdings Parent (CON) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-specialty outpatient facilities, nec · CIK 0002014596
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
166
13F, latest reported quarter
What the filings say about CON
Insiders, 180 days
-$14.6M net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-09-25
Planned sales (Form 144), 90 days
$4.1M
1 notice
Concentra Group Holdings Parent insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Concentra Group Holdings Parent, Inc. insiders sold a net $14.6M of stock across 4 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 1, 2026.
- The trade is 25.8% of the 503,455 shares held after it.
- No other insider sold within 30 days.
- 166 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ORTENZIO ROBERT A sold about $4.1M of CON on Aug 3, 2026, the largest insider sale at the company on our record; 166 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 1, 2026.
- The trade is 20.5% of the 633,455 shares held after it.
- No other insider sold within 30 days.
- 166 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ORTENZIO ROBERT A sold about $4.0M of CON on Jul 1, 2026, the largest insider sale at the company on our record; 166 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 8, 2026.
- The trade is 17.0% of the 763,455 shares held after it.
- No other insider sold within 30 days.
- 166 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ORTENZIO ROBERT A sold about $3.2M of CON on Jun 1, 2026; 166 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 14.6% of the 893,455 shares held after it.
- No other insider sold within 30 days.
- 166 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ORTENZIO ROBERT A sold about $3.2M of CON on May 8, 2026, the largest insider sale at the company on our record; 166 funds added in the latest 13F quarter.4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$14.6M over 180 days
-$4.1M over 90 days
below 75% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
166 funds bought in last quarter
more than 68% of Healthcare Services
Revenue
+13.9% year over year
more than 56% of Healthcare Services
Margin
7.7% net margin
more than 81% of Healthcare Services
Buybacks
$22.4M repurchased, FY to 2025-12-31
below 65% of Healthcare Services
Short interest
3.1% of the float short (float per yahoo 2026-10-26) · 3.1 days to cover · settled 2026-09-30
below 54% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CON
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+91.1%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CON: institutional holders (13F)
13F holdings, latest reported quarter
17,753,714 sh
$528.2M
6,817,456 sh
$202.8M
5,129,815 sh
$152.6M
4,840,099 sh
$144.0M
3,256,435 sh
$96.9M
Congress trades in CON
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-09-25 · disclosed 27 days later
$1,001 - $15,000
Bought 2025-09-11 · disclosed 41 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CON planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
ORTENZIO ROBERT A
Filed 2026-08-03
$4.1M
ORTENZIO ROBERT A
Filed 2026-07-01
$15.9M
ORTENZIO ROBERT A
Filed 2026-06-30
$27.8K
ORTENZIO ROBERT A
Filed 2026-06-29
$166.8K
ORTENZIO ROBERT A
Filed 2026-06-26
$1.6M
CON mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
CRM SMALL CAP VALUE FUND
$1.7M position · as of 2026-07-31
2.3%
Ancora/Thelen Small-Mid Cap Fund
$4.5M position · as of 2026-06-30
1.9%
State Street(R) SPDR(R) S&P(R) Health Care Services ETF
$2.5M position · as of 2026-06-30
1.8%
Keeley Gabelli SMID Cap Value Fund
$424.0K position · as of 2026-06-30
1.8%
TRIBUTARY SMALL COMPANY FUND
$11.7M position · as of 2026-06-30
1.7%
MOA SMALL CAP VALUE FUND
$7.1M position · as of 2026-06-30
1.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $14.6M sold by insiders over 180 days, 166 funds added last quarter, $4.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CON financials
Revenue growth
+13.9%
XBRL, annual
Net margin
7.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.3B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CON
| FY Dec 2025 | $2.2B |
| FY Dec 2024 | $1.9B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $606.0M |
| Mar 2026 | $569.6M |
| Dec 2025 | $539.1M |
| Sep 2025 | $572.8M |
| Jun 2025 | $550.8M |
| Mar 2025 | $500.8M |
| Dec 2024 | $465.0M |
| Sep 2024 | $489.6M |
At each fiscal year end
Single quarter
Net margin, TTM
+8.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CON
| FY Dec 2025 | +7.7% |
| FY Dec 2024 | +8.8% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +10.8% |
| Mar 2026 | +8.9% |
| Dec 2025 | +6.4% |
| Sep 2025 | +8.4% |
| Jun 2025 | +8.1% |
| Mar 2025 | +7.8% |
| Dec 2024 | +4.6% |
| Sep 2024 | +9.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$267.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CON
| FY Dec 2025 | $197.1M |
| FY Dec 2024 | $210.3M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $119.5M |
| Mar 2026 | $9.9M |
| Dec 2025 | $98.5M |
| Sep 2025 | $39.4M |
| Jun 2025 | $63.2M |
| Mar 2025 | -$4.0M |
| Dec 2024 | $77.0M |
| Sep 2024 | $50.8M |
At each fiscal year end
Single quarter
Debt to equity
3.27x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity CON
| FY Dec 2025 | 3.98x |
| FY Dec 2024 | 5.33x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | n/a |
| Jun 2026 | 3.27x |
| Mar 2026 | 3.68x |
| Dec 2025 | 3.98x |
| Sep 2025 | 4.15x |
| Jun 2025 | 4.82x |
| Mar 2025 | 5.27x |
| Dec 2024 | 5.33x |
| Sep 2024 | 5.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.21x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt CON
| FY Dec 2025 | 0.18x |
| FY Dec 2024 | 0.19x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.21x |
| Mar 2026 | 0.18x |
| Dec 2025 | 0.18x |
| Sep 2025 | 0.16x |
| Jun 2025 | 0.16x |
| Mar 2025 | 0.15x |
| Dec 2024 | 0.19x |
| Sep 2024 | 0.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+48.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CON
| FY Dec 2025 | +49.8% |
| FY Dec 2024 | +23.2% |
| FY Dec 2023 | +16.8% |
| FY Dec 2022 | n/a |
| Jun 2026 | +48.5% |
| Mar 2026 | +48.6% |
| Dec 2025 | +49.8% |
| Sep 2025 | +46.2% |
| Jun 2025 | +18.8% |
| Mar 2025 | +20.8% |
| Dec 2024 | +23.2% |
| Sep 2024 | +62.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CON
| FY Dec 2025 | +6.2% |
| FY Dec 2024 | +6.9% |
| FY Dec 2023 | +7.8% |
| FY Dec 2022 | n/a |
| Jun 2026 | +6.8% |
| Mar 2026 | +6.3% |
| Dec 2025 | +6.2% |
| Sep 2025 | +5.8% |
| Jun 2025 | +5.7% |
| Mar 2025 | +6.1% |
| Dec 2024 | +6.9% |
| Sep 2024 | +7.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+15.5%
operating income after a 23.1% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital CON
| FY Dec 2025 | +14.6% |
| FY Dec 2024 | +10.9% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +15.5% |
| Mar 2026 | +14.4% |
| Dec 2025 | +14.6% |
| Sep 2025 | +13.1% |
| Jun 2025 | +9.8% |
| Mar 2025 | +9.8% |
| Dec 2024 | +10.9% |
| Sep 2024 | +13.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+14.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CON
| FY Dec 2025 | +14.1% |
| FY Dec 2024 | +14.3% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +14.6% |
| Mar 2026 | +14.0% |
| Dec 2025 | +14.1% |
| Sep 2025 | +13.6% |
| Jun 2025 | +13.7% |
| Mar 2025 | +13.9% |
| Dec 2024 | +14.3% |
| Sep 2024 | +13.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
25.32x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CON
| FY Dec 2025 | 15.14x |
| FY Dec 2024 | 13.36x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 19.19x |
| Mar 2026 | 15.43x |
| Dec 2025 | 15.14x |
| Sep 2025 | 17.89x |
| Jun 2025 | 17.73x |
| Mar 2025 | 16.56x |
| Dec 2024 | 13.36x |
| Sep 2024 | 13.89x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.4B
market value at close 2026-10-23 on 2026-07-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value CON
| FY Dec 2025 | $4.0B |
| FY Dec 2024 | $3.8B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $5.2B |
| Mar 2026 | $4.3B |
| Dec 2025 | $4.0B |
| Sep 2025 | $4.2B |
| Jun 2025 | $4.2B |
| Mar 2025 | $4.3B |
| Dec 2024 | $3.8B |
| Sep 2024 | $4.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.3%
TTM free cash flow over market value at close 2026-10-23
FCF yield CON
| FY Dec 2025 | +7.8% |
| FY Dec 2024 | +8.4% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +7.0% |
| Mar 2026 | +7.6% |
| Dec 2025 | +7.8% |
| Sep 2025 | +6.5% |
| Jun 2025 | +7.1% |
| Mar 2025 | +6.4% |
| Dec 2024 | +8.4% |
| Sep 2024 | +6.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.75x
P/E over trailing EPS growth of 34%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing CON
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.57x |
| Mar 2026 | 2.53x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.2B | $1.9B | $1.8B | $1.7B |
| Operating income | $334.0M | $304.8M | $287.6M | $258.5M |
| Net income | $166.4M | $166.5M | $179.9M | $166.7M |
| EPS (diluted) | 1.30 | 1.46 | 1.73 | 1.60 |
| Operating cash flow | $279.4M | $274.7M | $234.3M | $274.3M |
| Cash | $79.9M | $183.3M | $31.4M | n/a |
| Long-term debt | $1.6B | $1.5B | $3.3M | n/a |
| Buybacks | $22.4M | $15.4M | $0 | $0 |
| Dividends paid | $32.1M | $8.0M | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
CON Stock Sonar score 6/7 axes
Find similar shapesCompareCON ranks highest on profitability (80th percentile) and risk and compliance (70th), and lowest on insider conviction (12th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CON filings, in plain words
Are Concentra Group Holdings Parent insiders buying or selling CON?
In the 180 days to 2026-10-27, Concentra Group Holdings Parent insiders were net sellers, a net $14.6M across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded CON?
Yes, but not in the year to 2026-10-27; the latest on record is a sale by Lisa McClain dated 2025-09-25.
Are there planned insider sales of CON?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $4.1M of stock; the latest, by ORTENZIO ROBERT A, was filed 2026-08-03.
Read the full summary
In the 180 days to 2026-10-27, Concentra Group Holdings Parent insiders were net sellers of CON, a net $14.6M across purchases and sales reported on Form 4 by 1 seller. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Members of Congress have disclosed trades in CON, none in the last year; the latest on record is a sale by Lisa McClain dated 2025-09-25. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $4.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
